Focus Partners Wealth Grows Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Focus Partners Wealth grew its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 431.7% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 79,499 shares of the company's stock after acquiring an additional 64,548 shares during the period. Focus Partners Wealth's holdings in Takeda Pharmaceutical were worth $1,054,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the company. Cornerstone Select Advisors LLC bought a new stake in Takeda Pharmaceutical during the 4th quarter valued at $167,000. Cubist Systematic Strategies LLC purchased a new position in shares of Takeda Pharmaceutical during the fourth quarter valued at $5,915,000. Cetera Investment Advisers raised its holdings in shares of Takeda Pharmaceutical by 14.7% in the fourth quarter. Cetera Investment Advisers now owns 59,273 shares of the company's stock valued at $785,000 after acquiring an additional 7,574 shares in the last quarter. Balyasny Asset Management L.P. purchased a new stake in Takeda Pharmaceutical in the fourth quarter worth about $2,558,000. Finally, BNP Paribas Financial Markets grew its holdings in Takeda Pharmaceutical by 15,449.0% during the 4th quarter. BNP Paribas Financial Markets now owns 500,677 shares of the company's stock worth $6,629,000 after acquiring an additional 497,457 shares in the last quarter. Hedge funds and other institutional investors own 9.17% of the company's stock.

Wall Street Analyst Weigh In

Separately, Morgan Stanley raised shares of Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research report on Wednesday, April 2nd.

Takeda Pharmaceutical Stock Up 0.4%

TAK stock traded up $0.06 during trading on Wednesday, hitting $14.33. 1,241,741 shares of the company's stock traded hands, compared to its average volume of 1,917,724. The firm has a market capitalization of $45.58 billion, a P/E ratio of 35.81, a PEG ratio of 0.24 and a beta of 0.26. Takeda Pharmaceutical Company Limited has a 1 year low of $12.58 and a 1 year high of $15.43. The company has a quick ratio of 0.72, a current ratio of 1.31 and a debt-to-equity ratio of 0.63. The business has a fifty day simple moving average of $14.73 and a two-hundred day simple moving average of $14.01.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.24 by ($0.08). The company had revenue of $7.34 billion for the quarter, compared to the consensus estimate of $8.02 billion. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. Sell-side analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.